Search for:

In brief

By way of background, kratom (Mitragyna speciosa (Korth.) Havil.) is a tropical tree with opioid properties and some stimulant-like effects, and was previously controlled under the Narcotics Act due to these properties and effects.

On 26 May 2021, the Amendment to the Narcotics Act (the “Amendment“) was published in the Government Gazette. The Amendment, once effective after 90 days from its publication, will remove kratom from being Category V Narcotics. The rationale behind this Amendment is to make the regulation of kratom in line with the position of the Single Convention on Narcotic Drugs of 1961, as amended, and the local customs in some areas where kratom is consumed.


Following the removal of kratom from the list of Category V Narcotics, on 1 June 2021, the Cabinet approved the amended draft of the Kratom Act to be considered for presentation to the Parliament. The draft Kratom Act is expected to include specific regulations on kratom, including growing/manufacturing, sale, import and export of kratom for industrial purposes and related licensing requirements and penalties for violation of the law.

We are monitoring the developments in this area and will keep you informed.

Author

Peerapan Tungsuwan is a corporate and M&A partner in Bangkok office with specialties in highly regulated industries, including the healthcare industry. She is currently Chair of the AEC Healthcare Harmonization Sub-committee of Baker McKenzie's Asia Pacific Healthcare Industry Group, of which she was head from 2007-2013. Within the Bangkok office, she heads the Healthcare Industry and Natural Resources Groups and co-leads the Mergers & Acquisitions practice group and Japan Advisory Group.

Author

Panyavith assists major local and multinational clients in a range of heavily regulated industries, such as healthcare & life sciences, chemical and biotech, on large complex mergers and acquisitions, private equity transactions, joint ventures, corporate restructurings, post-acquisition integration projects, commercial agreements and regulatory issues. With his technical and commercial astute, Panyavith has often been involved in a number of pioneering projects, helping clients navigate the challenges of uncharted waters and emerging opportunities with innovative solutions. He is recently recognized as "Up and Coming for Corporate and M&A" in Thailand by Chambers Asia-Pacific 2023.

Author

Praween Chantanakomes is an associate at Baker & McKenzie’s Bangkok office. He was admitted in 2008. He is currently active in the Corporate & Commercial, Mergers & Acquisitions, Environment, Natural Resources, and Pharmaceuticals practice groups.

Author

Prim Uditananda is a Regulatory Affairs Manager in Baker McKenzie, Bangkok office.

Write A Comment